Spotlight on Urology

Credits: 1.00 CME / CNE / CPE
Expert Perspectives on Navigating the Complex Treatment Landscape of Advanced Prostate Cancer
Ulka Vaishampayan, MD
Rush University Medical Center

Expert Perspectives on Navigating the Complex Treatment Landscape of Advanced Prostate Cancer

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: January 26, 2021
Expires: January 25, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with prostate cancer.

Learning Objectives

After completing this program, participants should be able to:

  1. Assess the latest advances in mHSPC and CRPC treatment paradigms including the efficacy, safety, selection, and application of new and emerging approaches in order to best integrate them into care
  2. Differentiate among available and emerging treatment approaches for mHSPC and CRPC
  3. Formulate best-practice treatment strategies for mHSPC and CRPC, taking into consideration current guidelines and expert recommendations when individualizing treatment plans

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the managementof prostate cancer.This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

In the past decade, the treatment landscape for advanced prostate cancer has changed dramatically with the introduction of various agents that have demonstrated a survival benefit. Several new agents have received FDA approval for the treatment of advanced prostate cancer, newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), novel endrocrine therapies that deprive or block prostate cancers from the effects of androgens, immunotherapeutic strategies that act to induce antitumor responses, new radiopharmaceuticals to target bony metastases, and novel chemotherapeutic agents. Many of these agents are currently in clinical trials to assess their applicability to different phases of the treatment paradigm in an effort to prolong survival while maintaining the patients’ quality of life.

The multitude of agents available for treating different prostate disease states and the rapid pace of new FDA approvals often confound clinical decision making. This educational activity aims to address these gaps in clinician knowledge to improve outcomes for patients with advanced prostate cancer.

Faculty

Ulka Vaishampayan, MD
Chair, Phase I Therapeutics
Rogel Cancer Center
Professor of Medicine
University of Michigan
Ann Arbor, MI


Conflict of Interest Policy/Disclosure Statement

Dr. Vaishampayan has consulted and honoraria for: Bayer, Merck, BMS, Exelixis, Alkermes, and Onclive

Dr. Vaishampayan has research grants from: Merck and BMS

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test.

Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by an educational grant from Sanofi-Genyzme.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: January 26, 2021
Expires: January 25, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with prostate cancer.

Learning Objectives

After completing this program, participants should be able to:

  1. Assess the latest advances in mHSPC and CRPC treatment paradigms including the efficacy, safety, selection, and application of new and emerging approaches in order to best integrate them into care
  2. Differentiate among available and emerging treatment approaches for mHSPC and CRPC
  3. Formulate best-practice treatment strategies for mHSPC and CRPC, taking into consideration current guidelines and expert recommendations when individualizing treatment plans

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the managementof prostate cancer.This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

In the past decade, the treatment landscape for advanced prostate cancer has changed dramatically with the introduction of various agents that have demonstrated a survival benefit. Several new agents have received FDA approval for the treatment of advanced prostate cancer, newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), novel endrocrine therapies that deprive or block prostate cancers from the effects of androgens, immunotherapeutic strategies that act to induce antitumor responses, new radiopharmaceuticals to target bony metastases, and novel chemotherapeutic agents. Many of these agents are currently in clinical trials to assess their applicability to different phases of the treatment paradigm in an effort to prolong survival while maintaining the patients’ quality of life.

The multitude of agents available for treating different prostate disease states and the rapid pace of new FDA approvals often confound clinical decision making. This educational activity aims to address these gaps in clinician knowledge to improve outcomes for patients with advanced prostate cancer.

Faculty

Ulka Vaishampayan, MD
Chair, Phase I Therapeutics
Rogel Cancer Center
Professor of Medicine
University of Michigan
Ann Arbor, MI


Conflict of Interest Policy/Disclosure Statement

Dr. Vaishampayan has consulted and honoraria for: Bayer, Merck, BMS, Exelixis, Alkermes, and Onclive

Dr. Vaishampayan has research grants from: Merck and BMS

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test.

Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by an educational grant from Sanofi-Genyzme.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Urology Presentations

1.00 CME / CNE / CPE
Rush University Medical Center
Navigating the Continuum of Care for Advanced Prostate Cancer (mHSPC, CRPC)

Navigating the Continuum of Care for Advanced Prostate Cancer (mHSPC, CRPC)

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: February 18, 2021
Expires: February 17, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with advanced prostate cancer.

Learning Objectives

After completing this program, participants should be able to:

  1. Explain the different treatment modalities for treating advanced and metastatic prostate cancer including hormonal, cytotoxic, immunologic, targeted, bone-directed, and investigational therapies
  2. Describe and implement the latest advances in the management of advanced prostate cancer across the disease continuum
  3. Personalize treatment decisions for patients with advanced and metastatic prostate cancer based on patient-specific factors, latest best-practice treatment strategies, recent clinical trial data, and expert recommendations

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the managementadvanced prostate cancer. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

With the exception of skin cancer, prostate cancer remains the most common cause of cancer in American men. The majority of patients diagnosed will seek treatment through surgery or radiation, and among those patients, approximately one-third will experience disease recurrence as indicated by elevated prostate specific antigen (PSA). Although androgen deprivation therapy (ADT) achieves temporary tumor control or regression in 90% of these individuals, most patients will ultimately progress to the advanced and/or fatal stage of malignancy, known as castrate-resistant prostate cancer (CRPC), in which the disease spreads to the regional lymph nodes, seminal vesicles, and distant sites such as the bones.

In the past decade, the treatment landscape for advanced prostate cancer has changed dramatically with the introduction of various agents that have demonstrated a survival benefit. Many agents have received FDA approval for the treatment of advanced prostate cancer, including early taxanes, novel endocrine therapies that deprive or block prostate cancers from the effects of androgens, immunotherapeutic strategies that act to induce antitumor responses, new radiopharmaceuticals to target bony metastases, and novel targeted therapies.  These agents are currently in clinical trials to assess their applicability to different phases of the treatment paradigm, either alone or in combination, in an effort to prolong survival while maintaining the patients’ quality of life.  Other novel agents are in late-phase clinical development and are likely to enter the clinic in the near future.

As understanding of the underlying pathology of advanced prostate cancer is further elucidated, the importance of genetic testing (genomic and somatic) to identify biomarkers is playing an increasing role in risk assessment and treatment selection. However, many treatments lack definitive biomarkers and clinicians must rely on their understanding of current best-practice approaches to guide treatment selection for individual patients with advanced prostate cancer. Frequently updated guidelines, along with an increasing number of available agents and the rapid pace of new FDA approvals has challenged many busy clinicians in their ability to stay up to date with current best-practice treatment approaches, which in turn may negatively impact patient outcomes.

This activity aims to address these gaps in clinician knowledge to improve outcomes for patients with advanced and metastatic prostate cancer.

Faculty

Robert Dreicer, MD, MS, MACP, FASCO
Head, Medical Oncology Section
Associate Director for Clinical Research and Deputy Director
University of Virginia Cancer Center
Co-Director Mellon Urologic Institute
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville, Virginia

Conflict of Interest Policy/Disclosure Statement

Dr. Dreicer has served on advisory boards for, Eisai, Janssen, Seattle Genetics, Genentech/Roche, Azuri, Astra Zeneca, Orion, and Novartis

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test.

Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This educational activity is supported by a medical education grant from Advanced Accelerator Applications, Astellas and Pfizer, Inc., Bayer Healthcare Pharmaceuticals, Inc., Exelixis, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., and Sanofi-Genzyme.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: February 18, 2021
Expires: February 17, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with advanced prostate cancer.

Learning Objectives

After completing this program, participants should be able to:

  1. Explain the different treatment modalities for treating advanced and metastatic prostate cancer including hormonal, cytotoxic, immunologic, targeted, bone-directed, and investigational therapies
  2. Describe and implement the latest advances in the management of advanced prostate cancer across the disease continuum
  3. Personalize treatment decisions for patients with advanced and metastatic prostate cancer based on patient-specific factors, latest best-practice treatment strategies, recent clinical trial data, and expert recommendations

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the managementadvanced prostate cancer. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

With the exception of skin cancer, prostate cancer remains the most common cause of cancer in American men. The majority of patients diagnosed will seek treatment through surgery or radiation, and among those patients, approximately one-third will experience disease recurrence as indicated by elevated prostate specific antigen (PSA). Although androgen deprivation therapy (ADT) achieves temporary tumor control or regression in 90% of these individuals, most patients will ultimately progress to the advanced and/or fatal stage of malignancy, known as castrate-resistant prostate cancer (CRPC), in which the disease spreads to the regional lymph nodes, seminal vesicles, and distant sites such as the bones.

In the past decade, the treatment landscape for advanced prostate cancer has changed dramatically with the introduction of various agents that have demonstrated a survival benefit. Many agents have received FDA approval for the treatment of advanced prostate cancer, including early taxanes, novel endocrine therapies that deprive or block prostate cancers from the effects of androgens, immunotherapeutic strategies that act to induce antitumor responses, new radiopharmaceuticals to target bony metastases, and novel targeted therapies.  These agents are currently in clinical trials to assess their applicability to different phases of the treatment paradigm, either alone or in combination, in an effort to prolong survival while maintaining the patients’ quality of life.  Other novel agents are in late-phase clinical development and are likely to enter the clinic in the near future.

As understanding of the underlying pathology of advanced prostate cancer is further elucidated, the importance of genetic testing (genomic and somatic) to identify biomarkers is playing an increasing role in risk assessment and treatment selection. However, many treatments lack definitive biomarkers and clinicians must rely on their understanding of current best-practice approaches to guide treatment selection for individual patients with advanced prostate cancer. Frequently updated guidelines, along with an increasing number of available agents and the rapid pace of new FDA approvals has challenged many busy clinicians in their ability to stay up to date with current best-practice treatment approaches, which in turn may negatively impact patient outcomes.

This activity aims to address these gaps in clinician knowledge to improve outcomes for patients with advanced and metastatic prostate cancer.

Faculty

Robert Dreicer, MD, MS, MACP, FASCO
Head, Medical Oncology Section
Associate Director for Clinical Research and Deputy Director
University of Virginia Cancer Center
Co-Director Mellon Urologic Institute
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville, Virginia

Conflict of Interest Policy/Disclosure Statement

Dr. Dreicer has served on advisory boards for, Eisai, Janssen, Seattle Genetics, Genentech/Roche, Azuri, Astra Zeneca, Orion, and Novartis

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test.

Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This educational activity is supported by a medical education grant from Advanced Accelerator Applications, Astellas and Pfizer, Inc., Bayer Healthcare Pharmaceuticals, Inc., Exelixis, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., and Sanofi-Genzyme.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

1.00 CME / CNE / CPE
Rush University Medical Center
Expert Perspectives on Navigating the Complex Treatment Landscape of Advanced Prostate Cancer

Expert Perspectives on Navigating the Complex Treatment Landscape of Advanced Prostate Cancer

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: January 26, 2021
Expires: January 25, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with prostate cancer.

Learning Objectives

After completing this program, participants should be able to:

  1. Assess the latest advances in mHSPC and CRPC treatment paradigms including the efficacy, safety, selection, and application of new and emerging approaches in order to best integrate them into care
  2. Differentiate among available and emerging treatment approaches for mHSPC and CRPC
  3. Formulate best-practice treatment strategies for mHSPC and CRPC, taking into consideration current guidelines and expert recommendations when individualizing treatment plans

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the managementof prostate cancer.This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

In the past decade, the treatment landscape for advanced prostate cancer has changed dramatically with the introduction of various agents that have demonstrated a survival benefit. Several new agents have received FDA approval for the treatment of advanced prostate cancer, newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), novel endrocrine therapies that deprive or block prostate cancers from the effects of androgens, immunotherapeutic strategies that act to induce antitumor responses, new radiopharmaceuticals to target bony metastases, and novel chemotherapeutic agents. Many of these agents are currently in clinical trials to assess their applicability to different phases of the treatment paradigm in an effort to prolong survival while maintaining the patients’ quality of life.

The multitude of agents available for treating different prostate disease states and the rapid pace of new FDA approvals often confound clinical decision making. This educational activity aims to address these gaps in clinician knowledge to improve outcomes for patients with advanced prostate cancer.

Faculty

Ulka Vaishampayan, MD
Chair, Phase I Therapeutics
Rogel Cancer Center
Professor of Medicine
University of Michigan
Ann Arbor, MI


Conflict of Interest Policy/Disclosure Statement

Dr. Vaishampayan has consulted and honoraria for: Bayer, Merck, BMS, Exelixis, Alkermes, and Onclive

Dr. Vaishampayan has research grants from: Merck and BMS

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test.

Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by an educational grant from Sanofi-Genyzme.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: January 26, 2021
Expires: January 25, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with prostate cancer.

Learning Objectives

After completing this program, participants should be able to:

  1. Assess the latest advances in mHSPC and CRPC treatment paradigms including the efficacy, safety, selection, and application of new and emerging approaches in order to best integrate them into care
  2. Differentiate among available and emerging treatment approaches for mHSPC and CRPC
  3. Formulate best-practice treatment strategies for mHSPC and CRPC, taking into consideration current guidelines and expert recommendations when individualizing treatment plans

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the managementof prostate cancer.This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

In the past decade, the treatment landscape for advanced prostate cancer has changed dramatically with the introduction of various agents that have demonstrated a survival benefit. Several new agents have received FDA approval for the treatment of advanced prostate cancer, newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), novel endrocrine therapies that deprive or block prostate cancers from the effects of androgens, immunotherapeutic strategies that act to induce antitumor responses, new radiopharmaceuticals to target bony metastases, and novel chemotherapeutic agents. Many of these agents are currently in clinical trials to assess their applicability to different phases of the treatment paradigm in an effort to prolong survival while maintaining the patients’ quality of life.

The multitude of agents available for treating different prostate disease states and the rapid pace of new FDA approvals often confound clinical decision making. This educational activity aims to address these gaps in clinician knowledge to improve outcomes for patients with advanced prostate cancer.

Faculty

Ulka Vaishampayan, MD
Chair, Phase I Therapeutics
Rogel Cancer Center
Professor of Medicine
University of Michigan
Ann Arbor, MI


Conflict of Interest Policy/Disclosure Statement

Dr. Vaishampayan has consulted and honoraria for: Bayer, Merck, BMS, Exelixis, Alkermes, and Onclive

Dr. Vaishampayan has research grants from: Merck and BMS

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test.

Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by an educational grant from Sanofi-Genyzme.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

0.75 CME
Integrity Continuing Education, Inc.
New Choices in Targeted Treatments for Advanced or Metastatic Urothelial Carcinoma: Plot Your Own Course

New Choices in Targeted Treatments for Advanced or Metastatic Urothelial Carcinoma: Plot Your Own Course

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: November 23, 2020
Expires: November 23, 2021
45 minutes to complete

Accredited By

Target Audience

This educational initiative has been designed for genitourinary oncologists, medical oncologists, surgical oncologists, radiologists, urologists, nurse practitioners (NPs), physician assistants (PAs), clinical nurse specialists (CNSs), advanced practice nurses (APNs), oncology clinical nurses (OCNs), and clinical oncology pharmacists (BCOPs) involved in the care and coordination of patients with urothelial carcinoma (UC).

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Articulate the mechanisms of action of targeted biopharmacologics and immune checkpoint inhibitors (ICIs) used in the treatment of UC
  • Outline efficacy and safety findings from key clinical trials of approved and investigational novel treatments developed for the treatment of advanced or metastatic UC (mUC)

Statement of Educational Need

In advanced or metastatic urothelial carcinoma (UC) a heavily cytotoxic “sledgehammer” approach has traditionally been used. Platinum-based chemotherapy is still the preferred first-line approach. But this non-specific cytotoxic treatment is often intolerable for the typically older UC patient.

Until recently, there were no second-line options beyond the chemotherapeutic sledgehammer. Today, treatments with more selective mechanisms of action take advantage of fresh translational insights into UC.

These novel therapeutics offer more efficient targeting for patients who have run out of options. But for clinicians, the introduction of these agents complicates an already complex condition. This activity will guide them in selecting and using these options.

In this case-based activity you will navigate a simulated patient case, making clinical decisions when prompted. Feedback regarding your decisions will be provided as you move through the case.

Co-Chairs

Thomas Powles, MBBS, MRCP, MD
Professor, Centre of Experimental Cancer Medicines
Bart’s Cancer Institute
St. Bartholomew’s Hospital
London, United Kingdom


Brian Rini, MD, FASCO
Chief of Clinical Trials
Department of Hematology/Oncology
Vanderbilt University Medical Center
Nashville, Tennessee


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Thomas Powell, MD:
Consulting Fees:
AstraZeneca, Bristol Myers Squibb, Exelixis, Incyte, Ipsen, Merck/Merck Sharp & Dohme, Novartis, Pfizer, Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, Eisai, and Roche
Contracted Research: AstraZeneca, Roche, Bristol Myers Squibb, Exelixis, Ipsen, Merck/Merck Sharp & Dohme, Novartis, Pfizer, Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, and Eisai
Other: Expenses/Travel/Accommodation: Roche, Pfizer, Merck Sharp & Dohme, AstraZeneca, and Ipsen

Brian Rini, MD:
Consulting Fees:
Merck, Pfizer, Bristol Myers Squibb, Aravive, AVEO Pharmaceuticals, GlaxoSmithKline
Contracted Research: Merck, Bristol Myers Squibb, Exelixis, Pfizer, AstraZeneca

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.

Designation of Credit

Integrity Continuing Education, Inc designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of November 23, 2020 through November 23, 2021, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 75% or better.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc., EMD, Serono, Inc., and Pfizer, Inc. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

Statement of Commercial Support

Supported by an educational grant from EMD Serono, Inc. and Pfizer, Inc.

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: November 23, 2020
Expires: November 23, 2021
45 minutes to complete

Accredited By

Target Audience

This educational initiative has been designed for genitourinary oncologists, medical oncologists, surgical oncologists, radiologists, urologists, nurse practitioners (NPs), physician assistants (PAs), clinical nurse specialists (CNSs), advanced practice nurses (APNs), oncology clinical nurses (OCNs), and clinical oncology pharmacists (BCOPs) involved in the care and coordination of patients with urothelial carcinoma (UC).

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Articulate the mechanisms of action of targeted biopharmacologics and immune checkpoint inhibitors (ICIs) used in the treatment of UC
  • Outline efficacy and safety findings from key clinical trials of approved and investigational novel treatments developed for the treatment of advanced or metastatic UC (mUC)

Statement of Educational Need

In advanced or metastatic urothelial carcinoma (UC) a heavily cytotoxic “sledgehammer” approach has traditionally been used. Platinum-based chemotherapy is still the preferred first-line approach. But this non-specific cytotoxic treatment is often intolerable for the typically older UC patient.

Until recently, there were no second-line options beyond the chemotherapeutic sledgehammer. Today, treatments with more selective mechanisms of action take advantage of fresh translational insights into UC.

These novel therapeutics offer more efficient targeting for patients who have run out of options. But for clinicians, the introduction of these agents complicates an already complex condition. This activity will guide them in selecting and using these options.

In this case-based activity you will navigate a simulated patient case, making clinical decisions when prompted. Feedback regarding your decisions will be provided as you move through the case.

Co-Chairs

Thomas Powles, MBBS, MRCP, MD
Professor, Centre of Experimental Cancer Medicines
Bart’s Cancer Institute
St. Bartholomew’s Hospital
London, United Kingdom


Brian Rini, MD, FASCO
Chief of Clinical Trials
Department of Hematology/Oncology
Vanderbilt University Medical Center
Nashville, Tennessee


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Thomas Powell, MD:
Consulting Fees:
AstraZeneca, Bristol Myers Squibb, Exelixis, Incyte, Ipsen, Merck/Merck Sharp & Dohme, Novartis, Pfizer, Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, Eisai, and Roche
Contracted Research: AstraZeneca, Roche, Bristol Myers Squibb, Exelixis, Ipsen, Merck/Merck Sharp & Dohme, Novartis, Pfizer, Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, and Eisai
Other: Expenses/Travel/Accommodation: Roche, Pfizer, Merck Sharp & Dohme, AstraZeneca, and Ipsen

Brian Rini, MD:
Consulting Fees:
Merck, Pfizer, Bristol Myers Squibb, Aravive, AVEO Pharmaceuticals, GlaxoSmithKline
Contracted Research: Merck, Bristol Myers Squibb, Exelixis, Pfizer, AstraZeneca

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.

Designation of Credit

Integrity Continuing Education, Inc designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of November 23, 2020 through November 23, 2021, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 75% or better.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc., EMD, Serono, Inc., and Pfizer, Inc. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

Statement of Commercial Support

Supported by an educational grant from EMD Serono, Inc. and Pfizer, Inc.